NDANASALSPRAY, METERED
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANCENASE AQ is a metered-dose nasal spray containing beclomethasone dipropionate monohydrate, a corticosteroid indicated for allergic and non-allergic rhinitis. It works by reducing inflammation and suppressing immune response in the nasal mucosa to relieve symptoms like congestion, sneezing, and rhinorrhea.
LOE Approaching
Product faces patent expiration with moderate competitive pressure (30% intensity), suggesting downsizing or transition planning for associated teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VANCENASE AQ offers limited career growth opportunities given its approaching loss of exclusivity and minimal linked job openings. Positions on this team are best suited for professionals seeking stable, established product management experience or those transitioning to newer assets within Merck's portfolio.
Brand ManagerField Sales Representative
Worked on VANCENASE AQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.